Australien - engelska - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sirolimus, quantity: 1 mg/ml - oral liquid, solution - excipient ingredients: polysorbate 80; propylene glycol; ethanol; ascorbyl palmitate; phosphatidyl choline; mono- and di- glycerides; soy fatty acids - indications as at 9 february 2004: rapamune is indicated for the prophylaxis of organ rejection in patients at mild to moderate immunological risk receiving renal transplants. therapeutic drug monitoring of sirolimus is required.

Storbritannien - engelska - MHRA (Medicines & Healthcare Products Regulatory Agency)

fdc international ltd - fluconazole - oral capsule - 150mg

Storbritannien - engelska - MHRA (Medicines & Healthcare Products Regulatory Agency)

fdc international ltd - fluconazole - oral capsule - 50mg

Australien - engelska - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - mycophenolate mofetil, quantity: 200 mg/ml - suspension - excipient ingredients: lecithin; sodium citrate dihydrate; colloidal anhydrous silica; xanthan gum; methyl hydroxybenzoate; aspartame; sorbitol; citric acid; flavour - alcept is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants.,alcept is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - mycophenolate mofetil, quantity: 200 mg/ml - suspension - excipient ingredients: sorbitol; sodium citrate dihydrate; citric acid; colloidal anhydrous silica; lecithin; aspartame; xanthan gum; methyl hydroxybenzoate; flavour - mycocell is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants.,mycocell is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - mycophenolate mofetil, quantity: 200 mg/ml - suspension - excipient ingredients: sorbitol; sodium citrate dihydrate; citric acid; methyl hydroxybenzoate; xanthan gum; aspartame; lecithin; colloidal anhydrous silica; flavour - pharmacor mycophenolate is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants.,pharmacor mycophenolate is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.

Israel - engelska - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - voriconazole - film coated tablets - voriconazole 50 mg - voriconazole - voriconazole - treatment of:- invasive aspergillosis,- fluconazole-resistant serious invasive candida infections (including c. krusei) - serious fungal infections caused by scedosporium spp. and fusarium spp.- vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. - treatment of candidemia in non neutropenic patients.- prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.

Irland - engelska - HPRA (Health Products Regulatory Authority)

flynn pharma limited - vancomycin - powder for concentrate for solution for infusion - 500 milligram(s) - glycopeptide antibacterials; vancomycin

Irland - engelska - HPRA (Health Products Regulatory Authority)

flynn pharma limited - vancomycin - powder for concentrate for solution for infusion - 1 gram(s) - glycopeptide antibacterials; vancomycin

Israel - engelska - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - voriconazole - film coated tablets - voriconazole 50 mg - voriconazole - treatment of:- invasive aspergillosis, - fluconazole-resistant serious invasive candida infections (including c. krusei)- serious fungal infections caused by scedosporium spp. and fusarium spp.- vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. - treatment of candidemia in non neutropenic patients.- prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.